S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.01 (+0.92%)
AAPL   116.59 (+0.48%)
MSFT   215.23 (+0.64%)
FB   277.81 (+0.81%)
GOOGL   1,787.02 (+1.30%)
AMZN   3,195.34 (+0.32%)
TSLA   585.76 (+2.05%)
NVDA   530.45 (+0.20%)
BABA   276.48 (-0.45%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.19 (+0.55%)
T   29.03 (+0.14%)
NIO   54.00 (+0.58%)
F   9.09 (+0.11%)
ACB   10.47 (+20.21%)
NFLX   491.36 (+1.31%)
GILD   60.03 (+0.89%)
BA   216.50 (-0.51%)
DIS   147.13 (-1.31%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.01 (+0.92%)
AAPL   116.59 (+0.48%)
MSFT   215.23 (+0.64%)
FB   277.81 (+0.81%)
GOOGL   1,787.02 (+1.30%)
AMZN   3,195.34 (+0.32%)
TSLA   585.76 (+2.05%)
NVDA   530.45 (+0.20%)
BABA   276.48 (-0.45%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.19 (+0.55%)
T   29.03 (+0.14%)
NIO   54.00 (+0.58%)
F   9.09 (+0.11%)
ACB   10.47 (+20.21%)
NFLX   491.36 (+1.31%)
GILD   60.03 (+0.89%)
BA   216.50 (-0.51%)
DIS   147.13 (-1.31%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.01 (+0.92%)
AAPL   116.59 (+0.48%)
MSFT   215.23 (+0.64%)
FB   277.81 (+0.81%)
GOOGL   1,787.02 (+1.30%)
AMZN   3,195.34 (+0.32%)
TSLA   585.76 (+2.05%)
NVDA   530.45 (+0.20%)
BABA   276.48 (-0.45%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.19 (+0.55%)
T   29.03 (+0.14%)
NIO   54.00 (+0.58%)
F   9.09 (+0.11%)
ACB   10.47 (+20.21%)
NFLX   491.36 (+1.31%)
GILD   60.03 (+0.89%)
BA   216.50 (-0.51%)
DIS   147.13 (-1.31%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.01 (+0.92%)
AAPL   116.59 (+0.48%)
MSFT   215.23 (+0.64%)
FB   277.81 (+0.81%)
GOOGL   1,787.02 (+1.30%)
AMZN   3,195.34 (+0.32%)
TSLA   585.76 (+2.05%)
NVDA   530.45 (+0.20%)
BABA   276.48 (-0.45%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.19 (+0.55%)
T   29.03 (+0.14%)
NIO   54.00 (+0.58%)
F   9.09 (+0.11%)
ACB   10.47 (+20.21%)
NFLX   491.36 (+1.31%)
GILD   60.03 (+0.89%)
BA   216.50 (-0.51%)
DIS   147.13 (-1.31%)
Log in
NYSEAMERICAN:NAVB

Navidea Biopharmaceuticals Stock Forecast, Price & News

$2.40
+0.06 (+2.56 %)
(As of 11/27/2020 01:36 PM ET)
Add
Compare
Today's Range
$2.33
Now: $2.40▼
$2.43
50-Day Range N/A
52-Week Range
$0.63
Now: $2.40▼
$5.36
Volume99,147 shs
Average Volume677,765 shs
Market Capitalization$64.05 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. The company also offers NAV4694, a fluorine-18 labeled PET imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimer's disease and mild cognitive impairment. In addition, it is developing diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.
Read More
Navidea Biopharmaceuticals logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.57 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNYSEAMERICAN:NAVB
Previous SymbolNYSEMKT:NAVB
CUSIP63937X10
CIK810509
Webwww.navidea.com
Phone+1-614-7937500
Employees13

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares26,687,000
Market Cap$64.05 million
Next Earnings Date3/10/2021 (Estimated)
OptionableOptionable
$2.40
+0.06 (+2.56 %)
(As of 11/27/2020 01:36 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NAVB News and Ratings via Email

Sign-up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Navidea Biopharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Navidea Biopharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Navidea Biopharmaceuticals.

What stocks does MarketBeat like better than Navidea Biopharmaceuticals?

Wall Street analysts have given Navidea Biopharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Navidea Biopharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Navidea Biopharmaceuticals' next earnings date?

Navidea Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021.
View our earnings forecast for Navidea Biopharmaceuticals.

How were Navidea Biopharmaceuticals' earnings last quarter?

Navidea Biopharmaceuticals, Inc. (NYSEAMERICAN:NAVB) released its earnings results on Thursday, November, 12th. The biopharmaceutical company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.04.
View Navidea Biopharmaceuticals' earnings history.

What price target have analysts set for NAVB?

2 brokerages have issued 12 month price targets for Navidea Biopharmaceuticals' stock. Their forecasts range from $7.00 to $8.00. On average, they expect Navidea Biopharmaceuticals' stock price to reach $7.50 in the next year. This suggests a possible upside of 212.5% from the stock's current price.
View analysts' price targets for Navidea Biopharmaceuticals.

Who are some of Navidea Biopharmaceuticals' key competitors?

Some companies that are related to Navidea Biopharmaceuticals include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), Baxter International (BAX), IDEXX Laboratories (IDXX), DexCom (DXCM), ResMed (RMD), Hologic (HOLX), Teleflex (TFX), Insulet (PODD) and STERIS (STE).
View all competitors.

What other stocks do shareholders of Navidea Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Navidea Biopharmaceuticals investors own include OPKO Health (OPK), Ampio Pharmaceuticals (AMPE), CorMedix (CRMD), Catalyst Pharmaceuticals (CPRX), FuelCell Energy (FCEL), Palatin Technologies (PTN), Trevena (TRVN), Agenus (AGEN), Dynavax Technologies (DVAX) and Genocea Biosciences (GNCA).

Who are Navidea Biopharmaceuticals' key executives?

Navidea Biopharmaceuticals' management team includes the following people:
  • Mr. Jed A. Latkin, CEO, COO, CFO & Director (Age 46, Pay $658.74k)
  • Dr. Michael Stanley Rosol Ph.D., Chief Medical Officer (Age 52, Pay $243.79k)
  • Erika Gibson, Director of Fin. & Admin.
  • Mr. William J. Regan, Chief Compliance Officer (Age 68)
  • Mr. Joel Harrison Kaufman, Head of Corp. Strategy & Bus. Devel.

What is Navidea Biopharmaceuticals' stock symbol?

Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB."

How do I buy shares of Navidea Biopharmaceuticals?

Shares of NAVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Navidea Biopharmaceuticals' stock price today?

One share of NAVB stock can currently be purchased for approximately $2.40.

How big of a company is Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals has a market capitalization of $64.05 million. Navidea Biopharmaceuticals employs 13 workers across the globe.

What is Navidea Biopharmaceuticals' official website?

The official website for Navidea Biopharmaceuticals is www.navidea.com.

How can I contact Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The biopharmaceutical company can be reached via phone at +1-614-7937500.

This page was last updated on 11/27/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.